

Central Lancashire Online Knowledge (CLOK)

Title	Omega-3 Fatty Acids Mitigating Isotretinoin-Induced Cheilitis
Type	Article
URL	https://clock.uclan.ac.uk/51625/
DOI	https://doi.org/10.1093/ced/llae197
Date	2024
Citation	Siripanich, Chawalpat, Chow, Yan-Ching and Ali, Faisal R (2024) Omega-3 Fatty Acids Mitigating Isotretinoin-Induced Cheilitis. Clinical and Experimental Dermatology, 49 (11). pp. 1444-1445. ISSN 0307-6938
Creators	Siripanich, Chawalpat, Chow, Yan-Ching and Ali, Faisal R

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1093/ced/llae197>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

Title: Omega-3 Fatty Acids Mitigating Isotretinoin-Induced Cheilitis

Running head: Omega-3 Fatty Acids Mitigating Isotretinoin-Induced Cheilitis

Authors: Chawalpat Siripanich^{1,2} , Yan Ching Chow^{1,2*} , Dr Faisal R. Ali ^{3,4}

Institutions:

¹ School of Medicine and Dentistry, University of Central Lancashire, Preston, Lancashire, PR1 2HE, United Kingdom

² National Centre of Remote and Rural Medicine, Moor Row, Cumbria, CA24 3JY, United Kingdom

³ Mid Cheshire NHS Foundation Trust, United Kingdom

⁴ St John's Institute of Dermatology, London, London, SE1 7EP, United Kingdom

Corresponding author: *Yan Ching Chow, ycchow@uclan.ac.uk, School of Medicine and Dentistry, University of Central Lancashire, Preston, PR1 2HE, United Kingdom

Source of Funding: None

Conflict of Interest: Dr Faisal R. Ali has received honoraria/fees for speaker activities and advisory work for Galderma and L'Oreal

Ethics Approval/ Informed Consent: Not Applicable

Word count: 438

Figure count: 0

Table count: 0

Article type: Letter to the Editor

Omega-3 Fatty Acids Mitigating Isotretinoin-Induced Cheilitis

Whilst isotretinoin is an effective treatment for severe acne vulgaris, isotretinoin induced cheilitis is one of the most troubling side effects of the treatment.¹ In their excellent review, which briefly covers the treatments for isotretinoin induced cheilitis, the authors have overlooked the utility of Omega-3 Fatty Acids (O3FA). O3FA, a cluster of long-chain and very-long-chain polyunsaturated fatty acids that the human body cannot synthesise intrinsically, have demonstrated efficacy in improving specific conditions characterised by inflammation, dryness, and moisture loss.² There are three main types of O3FA: α -linolenic acid (ALA; found in nuts, seeds, and vegetable oils), eicosapentaenoic acid (EPA; found in fish), and docosahexaenoic acid (DHA; found in fish).³ Evidence suggested that the consumption of O3FA may abrogate some of the mucocutaneous adverse effects of oral isotretinoin in individuals with acne with few adverse effects.² Although the mechanism is unclear, it may be due to anti-inflammatory properties as these fatty acids can modify cell membrane composition, inhibit pro-inflammatory transcription factors like nuclear factor κ B, and activate anti-inflammatory factors such as peroxisome proliferator-activated receptor γ , leading to a reduction in the expression of inflammatory genes and, in animal models, reduce transepidermal water loss.³ A 16-week case-controlled study² ($n = 104$; 64.4% females; mean age 22.8 years) suggested that patients with moderate-severe acne who take O3FA soft gel capsules (1 g/day) alongside isotretinoin (0.5 mg/kg) compared to isotretinoin of same dose alone had significantly reduced dry nose and dry skin (Week 0-16, $p < 0.05$), dry lips (Week 0-12, $p < 0.05$; statistically insignificant reduction in Week 12-16), and dry eyes (Week 0-4, $p < 0.05$; statistically insignificant reduction in Week 4-16). A separate randomised controlled trial⁴ on acne ($n = 60$; 66.7% female; mean age 26.1 years) recommended that O3FA (1 mg/kg) taken with isotretinoin (0.5 mg/kg) compared to isotretinoin monotherapy significantly reduces xerosis ($p < 0.001$) and dry lips ($p = 0.013$). No adverse effects of O3FA have been reported with either trial. Side effects of systematic isotretinoin such as dryness of the skin and mucosal surfaces can lead to non-concordance and discontinuation of medication.² Even though using a lower dose of isotretinoin may ameliorate some of these symptoms, this requires a longer course of isotretinoin, necessitating more follow-up appointments and a longer need to maintain pregnancy prevention measures and monitor psychosexual guidelines. Whilst the above studies are small in number and both efficacy and potential side effects need substantiation in larger trials, we would encourage dermatologists to consider suggesting the

use of this seemingly non-toxic nutraceutical adjunct to patients taking isotretinoin, as part of the holistic care of acne patients.

References

- 1.Narayanan D, Rogge M. Cheilitis: A Diagnostic Algorithm and Review of Underlying Etiologies. Dermatitis: Contact, Atopic, Occupational, Drug [Internet]. 2024 Feb 29; Available from: <https://pubmed.ncbi.nlm.nih.gov/38422211/>
- 2.Mirnezami M, Rahimi H. Is Oral Omega-3 Effective in Reducing Mucocutaneous Side Effects of Isotretinoin in Patients with Acne Vulgaris? Dermatology Research and Practice [Internet]. 2018 May 29;2018. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996413/>
- 3.Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions [Internet]. 2017 Sep 12;45(5):1105–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/28900017/>
- 4.Zainab Z, Malik NA, Obaid S, Malik S, Aftab K, Mumtaz M, et al. Effectiveness Of Oral Omega 3 In Reducing Mucocutaneous Side Effects Of Oral Isotretinoin In Patients With Acne Vulgaris. Journal of Ayub Medical College, Abbottabad: JAMC [Internet]. 2021;33(1):60–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/33774956/>